GPR20 was isolated as an orphan G protein-coupled receptor from genomic DNA by PCR amplification. Although GPR20 was closely related to nucleotide or lipid receptors, the functional role of this receptor, as well as its endogenous ligand, remain unclear. Here, we demonstrate that GPR20 is constitutively active in the absence of ligand, leading to continuous activation of its coupled G proteins. When GPR20 was exogenously expressed in HEK293 cells, both the basal level and the prostaglandin E 2 (PGE 2 )-induced production of cAMP were significantly decreased.
GPR20 was isolated as an orphan G protein-coupled receptor from genomic DNA by PCR amplification. Although GPR20 was closely related to nucleotide or lipid receptors, the functional role of this receptor, as well as its endogenous ligand, remain unclear. Here, we demonstrate that GPR20 is constitutively active in the absence of ligand, leading to continuous activation of its coupled G proteins. When GPR20 was exogenously expressed in HEK293 cells, both the basal level and the prostaglandin E 2 (PGE 2 )-induced production of cAMP were significantly decreased.
A remarkable increase in [ 35 S]guanosine 5'-( -thio) triphosphate (GTP S) binding to membrane preparations was also observed in GPR20-expressing cells.
These effects of GPR20 overexpression were diminished in cells treated with pertussis toxin, suggesting that the expression of GPR20 results in the activation of G i/o proteins. Involvement of GPR20 in the activation of G i/o proteins was also supported by evidence that the disruption of a conserved DRY motif in GPR20 attenuated both [ incorporation was also observed in the GPR20-silencing cells, implying that the GPR20 expression seems to attenuate PC12h cell growth. Taken together, these data indicate that GPR20 constitutively activates G i proteins without ligand stimulation. The receptor may be involved in cellular processes including control of intracellular cAMP levels and mitogenic signaling.
Mammalian G protein-coupled receptors (GPCRs) 2 are a diverse superfamily of proteins with hundreds of members, and these receptors regulate many processes in vivo via interactions with a variety of ligands including small organic molecules, lipids, protons, hormones, short and large polypeptides, glycoproteins, and even photons. Despite the vast and longstanding efforts of academic and industrial researchers to pair GPCRs with potential ligands, more than 150 non-sensory GPCRs still remain orphan receptors, for which the cognate ligands have not yet been identified (1) . Since GPCRs have proven particularly amenable to modulation by small molecules and are the targets of approximately half of currently marketed prescription drugs, the non-sensory GPCRs are clearly important therapeutic targets (2) . Consequently, the orphan GPCRs constitute a vast reservoir of potential drug targets for therapeutic development. Indeed, numerous research groups, including ours, work on characterizing these receptors. GPR20 is one of the orphan GPCRs that has been identified from human genomic DNA by PCR amplification using primers based on the sequences of the opioid/somatostatin related receptors, GPR7 and GPR8 (3) . The expression of human GPR20 has been detected in several brain regions, including the caudate nuclei, putamen and the thalamus (3) . A recently disclosed patent demonstrated that GPR20 deficient mice exhibited a hyperactivity disorder characterized by an increase in total distance traveled in an open field test (4) , implying a substantial role of GPR20 in neurophysiological function. However, the physiological mechanisms of GPR20 action, including the identification of natural ligands for GPR20, have not yet been elucidated. In this study, we show that GPR20 has the potential to constitutively activate G i -type G-proteins without extracellular ligands. Furthermore, the physiological relevance of this constitutive activation of GPR20 was confirmed by RNA interference experiments and mitogenic response assays.
EXPERIMENTAL PROCEDURES
Materials -Prostaglandin E 2 (PGE 2 ) was purchased from Cayman Chemical (Ann Arbor, MI).
3-Isobutyl-1-methylxanthine (IBMX), GDP, guanosine 5'-( -thio)triphosphate (GTP S), bovine serum albumin (BSA, fatty acid-free grade) and the M5 mouse monoclonal anti-FLAG antibody were purchased from Sigma (St. Louis, MO). Pertussis toxin (PTX) was obtained from List Biological Laboratories (Campbell, CA). Ex-Taq DNA Polymerase and restriction enzymes were purchased from Takara Bio (Tokyo, Japan). and SuperScriptII reverse transcriptase were purchased from Invitrogen (Carlsbad, CA). G418 was purchased from Wako (Osaka, Japan). KOD Dash DNA polymerase and KOD Plus DNA polymerase were purchased from TOYOBO (Tokyo, Japan).
Complete protease inhibitor mixture was purchased from Roche Diagnostics (Mannheim, Germany). The cAMP Biotrak EIA system was purchased from GE Healthcare (Buckinghamshire, UK). Construction of a Phylogenetic Tree -Amino acid sequences of selected human GPCRs were obtained from GenBank™ and SwissProt. The phylogenetic tree was generated from the amino acid sequences of these GPCRs using the allagainst-all matching method (available at cbrg.inf.ethz.ch/Server/AllAll.html).
The tree was constructed on the basis of point-accepted mutation distances between each pair of sequences estimated by the dynamic programming algorithm.
Construction of the Human GPR20 and BLT1
Expressing Plasmids -A DNA fragment containing the human GPR20 (hGPR20) gene (GenBank™ accession number NM_005293) was obtained from human genomic DNA by PCR amplification using the sense primer, 5'-ATGGAGAAGGGGGATGCTGGGC-3', and the antisense primer, 5'-TTCAGGCCACCACATCCCATCG-3'. For construction of the hGPR20 expression plasmid, the entire open reading frame of hGPR20 was amplified from the above DNA fragment by PCR using the sense primer, 5'-CAGGATATCCCCTCTGTGTCTCCAGCGGG-3', and the antisense primer, 5'-CAGGAATTCCTAAGCCTCGGGCCCATTAG-3', and subcloned into the EcoRV and EcoRI sites of the pCXN2.1-FLAG vector, a modified version of pCXN2 (5) . The resultant plasmid, designated pCXN2.1-FLAG-GPR20, was used to express an N-terminally FLAG-tagged hGPR20. For construction of the expression plasmid for human leukotriene B 4 type 1 receptor (hBLT1, GenBank™ accession number NM_181657), an entire open reading frame of hBLT1 was subcloned into the pCXN2.1-FLAG vector. Construction of Short Hairpin RNA Expressing Plasmids -Oligonucleotides for the construction of three short hairpin RNA (shRNA) plasmids directed against rat GPR20 (rGPR20) mRNA were designed using the siDirect siRNA design system provided by the RNAi Co. (Tokyo, Japan, available at www.rnai.co.jp).
The designed sequences are as follows:
sh1-sense, 5 '-GATCCCCCATCGTCTACTGTTTTATTCAAG  AGATAAAACAGTAGACGATGGGGTA-3';  sh1-antisense,  5'-AGCTTACCCCATCGTCTACTGTTTTATCTCT  TGAATAAAACAGTAGACGATGGGG-3'; sh2-sense,  5'-GATCCGACCCTGTCTGTATTGGGTTTCAAG  AGAACCCAATACAGACAGGGTCACA-3';  sh2-antisense,  5'-AGCTTGTGACCCTGTCTGTATTGGGTTCTC  TTGAAACCCAATACAGACAGGGTCG-3';  sh3-sense,  5'-GATCCCTCAGCACCGGTTCTCACATTATTC  AAGAGATGTGAGAACCGGTGCTGAGGAA-3'; sh3-antisense, 5'-AGCTTTCCTCAGCACCGGTTCTCACATCTC TTGAATAATGTGAGAACCGGTGCTGAGG-3'. After annealing the sense and antisense oligos, the resultant DNA fragments were subcloned into the BamHI and HindIII sites of the pSilencer 4.1-CMV hygro vector (purchased from Ambion (Austin, TX), abbreviated pSilencer), giving rise to three rGPR20-shRNA plasmids, pSilencer-sh1, pSilencer-sh2, and pSilencer-sh3. We used a negative control-shRNA plasmid supplied by Ambion as a control scrambled shRNA.
Construction of a Mutant hGPR20 (R148A)
Plasmid -Mutagenesis of GPR20 was performed via site-directed mutagenesis using a QuikChange Site-Directed Mutagenesis Kit (STRATAGENE) following the manufacturer's instructions, with the exception that the KOD Plus DNA polymerase (TOYOBO) was used for PCR amplification.
pCXN2.1-FLAG-GPR20 was used as a template plasmid and the primers for mutagenesis were as follows: R148A-sense, 5'-CTGCATCTGCGTGGACgccTACCTGGCCATC GTG-3'; R148A-antisense, 5'-CACGATGGCCAGGTAggcGTCCACGCAGAT GCAG-3'. The resultant construct was verified through complete DNA sequencing of both DNA strands.
Generation of PTX-resistant G i -GFP Fusion
Proteins -Expression plasmids for GFP-fused PTX-resistant G i1 , G i2 , and G i3 proteins (6) (7) (8) (9) (10) were constructed as follows.
The Cys 
Establishment of Cells Stably
Expressing hGPR20 -HEK293 cells were transfected with pCXN2.1-FLAG-GPR20 and cultured for 30 days in the presence of 1.0 mg/ml G418. These cells were incubated with 10 μg/ml anti-FLAG (M5) in phosphate-buffered saline (PBS) containing 2% goat serum for 30 min, followed by staining with Alexa Fluor 488-labeled antimouse IgG in PBS/2% goat serum for 15 min. Transformants highly expressing FLAG-hGPR20, designated HEK293-GPR20 cells, were collected as a polyclonal population by cell sorting using an EPICS ALTRA instrument (Beckman Coulter) and maintained in the presence of 0.3 mg/ml G418. Flow cytometric analyses of the FLAGhGPR20 expressing cells were performed using an EPICS XL instrument (Beckman Coulter To examine the expression of hGPR20 in human tissues, the amount of the GPR20 cDNA in each sample was evaluated using a TaqMan gene expression assay (Applied Biosystems, Foster City, CA; Assay ID: Hs00271049_s1) and the modified TaqMan Universal PCR Master Mix containing 0.01% BSA. The amount of cDNA was estimated using a LightCycler apparatus (Roche Diagnostics) and the Fit Points Method in the LightCycler analysis software.
For each evaluation, a specific standard curve was made using a series of dilutions from the corresponding cDNA. Mouse total RNAs were prepared from various tissues using an Absolutely RNA Miniprep Kit (Stratagene, La Jolla CA), and first strand cDNAs were synthesized using Superscript II. PCR amplifications were carried out in microcapillary tubes, in 20 μl reaction volumes consisting of 2 μl of cDNA solution, 1x FastStart DNA Master SYBR Green I (Roche Diagnostics) and 0.5 μM each of the forward and the reverse primers.
A 194-bp fragment of the mouse GPR20 (mGPR20) cDNA was generated using following primers:
forward primer, 5'-AAACCCAACCAGAAGAGTTCACC-3'; reverse primer, 5'-AAATGCCAACCAGATACCCAAGT-3'.
Evaluation of GPR20 Expression in Various
Cell Lines -Total RNA was isolated from cell lines using Isogen (Nippon Gene, Toyama, Japan), followed by purification of mRNAs using a poly (A) + Isolation Kit (Nippon Gene). cDNA was generated from 100 ng of the purified mRNA using Superscript II and random hexamer primers. A 187-bp fragment of hGPR20, a 194-bp fragment of mGPR20 and a 197-bp fragment of rGPR20 were generated by PCR. The primers used in these analyses were: hGPR20 sense primer, 5'-GCTGGCGCTGTACGTCTTCT-3', and antisense primer, 5'-CATGTTGAGGAAGTAACCGAGGA-3'; rGPR20, sense primer, 5'-GTCCTGGGCTACTTCCTCAACAT-3', and antisense primer, 5'-CCACCAGTCTTCACACCCAATAC-3'. The primers for mGPR20 were the same as described above. The primer sequences for -actin were: human, sense primer, 5'-CAGGATGCAGAAGGAGATCACTG-3', and antisense primer, 5'-TACTCCTGCTTGCTGATCCACAT-3'; rat, sense primer, 5'-AGACCTCTATGCCAACACAGTGC-3', and antisense primer, 5'-ATAGAGCCACCAATCCACACAGA-3'; mouse, sense primer, 5'-CACAGGCATTGTGATGGAC-3', and antisense primer, 5'-
Validation of RNA Interference -To validate the efficiency of the rGPR20-knockdown by pSilencer-sh1, pSilencer-sh2, or pSilencer-sh3, quantitative real time RT-PCR (qRT-PCR) was performed. Seven days after transfection of these plasmids into PC12h cells, mRNA isolation and cDNA synthesis was performed as described above. Using the resultant cDNAs, the amounts of expressed rGPR20 and -actin mRNAs were estimated using LightCycler Fast Start DNA Master PLUS SYBR Green I (Roche Diagnostics)
according to the manufacturer's protocol. In these experiments, the primers for -actin were the same as described above.
For each evaluation, a specific standard curve was made using a series of dilutions of the corresponding cDNA. 
RESULTS
Cloning of the hGPR20 Gene -We cloned human GPR20 from human genomic DNA by PCR amplification. However, several sequences in our cloned hGPR20 were different from the reported GPR20 sequence (3 We used our hGPR20 clone in this study, because we verified the sequences of several independently isolated hGPR20 clones and the same sequence was recently deposited in the human total genome sequence database at NCBI (accession number NT_008046). The primary structure of hGPR20 exhibited 82.8% and 81.4% amino acid identity to mouse and rat GPR20, respectively (Fig. 1A) . Phylogenetic analysis revealed that hGPR20 was closely related to functional receptors for nucleotides or lipids (e.g., TG1019, CysLT1, CysLT2, LPA4, LPA5, GPR34 and PAF receptors, Fig. 1B ), raising the possibility that GPR20 may recognize nucleotides or lipids as ligands.
Tissue and Cellular Expression of GPR20 mRNA -Using cDNAs prepared from 16 human tissues, qRT-PCR was performed to evaluate the expression of hGPR20.
In these tissues, hGPR20 was ubiquitously expressed, with the highest expression in small intestine ( Fig. 2A) . Similarly, mouse GPR20 mRNA was detected in a broad range of tissues with abundant expression in intestinal tissues, such as small intestine and colon (Fig. 2B) . GPR20 mRNA was detected in various cell lines, including N1E115 (mouse neuroblastoma cells), B103 (rat neuroblastoma cells), PC12 and PC12h (rat pheochromocytoma cells), U937 (human histiocytic lymphoma cells), HL60 (human acute promyelocytic leukemia cells) and COLO320 (human colon adenocarcinoma cells), expressed detectable levels of the GPR20 mRNA (Fig. 2C) . One of these cell lines, PC12h, was used for the GPR20-knockdown experiments shown below.
Reduction of cAMP Formation by the Expression of hGPR20 -Because GPR20 belongs to a family of lipid/nucleotiderecognizing receptors, we carried out a ligand screening using the BIOMOL Screen-Well™ Bioactive Lipid Library (purchased from BIOMOL) and 17 nucleotides (Sigma).
To facilitate this screening, we constructed an expression plasmid producing an N-terminally FLAG-tagged hGPR20 (FLAG-hGPR20), and established a HEK293 cell line stably expressing FLAG-hGPR20 (HEK293-GPR20 cells). Prior to screening, expression of FLAG-hGPR20 on the cell surface of HEK293-GPR20 cells was validated by flow cytometric analysis (Fig. 3A) . Although we evaluated the agonistic activity of 198 lipids and 17 nucleotides using HEK293-GPR20 cells by monitoring intracellular calcium mobilization and cAMP formation, none of them was an effective agonist for hGPR20 (data not shown). Furthermore, FLAG-hGPR20 did not respond to changes in the extracellular pH (data not shown), even though GPR20 is closely related to the four proton-sensing GPCRs, i.e., G2A, GPR4, OGR1 and TDAG8 (12) (13) (14) (15) in the phylogenetic tree.
Additionally, we did not observe any activation of GPR20 by several steroid hormones, including hydrocortisone, corticosterone, -estradiol, and progesterone (data not shown). During the course of these experiments, we unexpectedly detected a modest but significant decrease in basal cAMP level in HEK293-GPR20 cells, compared to that of vector-transfected cells (Fig. 3B) . Moreover, we observed that the FLAG-hGPR20 expression resulted in attenuated PGE 2 -stimulated cAMP formation in comparison to vector-transfected cells (Fig. 3C) . Similar effects were observed in HEK293 cells transiently expressing FLAGhGPR20 (Fig. 3E) , implying that these observations were not an artifact of the cloned cell lines. Because the above effects by FLAGhGPR20 expression were abolished by treatment with PTX (Fig. 3B, D and E (16, 17) . As shown in Figure 4A , transfection of hGPR20 enhanced [ (Fig.  4B) , which is consistent with the PTX-sensitivity of PGE 2 -induced cAMP formation in GPR20 transfected cells (Fig. 3B-E) . To provide further evidence for the activation of G i proteins by hGPR20, we examined whether [ 35 S]GTP S incorporation into exogenously expressed PTXresistant mutants of G i protein (the G i1 , G i2 and G i3 ) (6-10), increased in FLAG-hGPR20 expressing cells. As shown in Figure 4C , even in cells pretreated with PTX, increasing [ 35 S]GTP S binding to the PTX-resistant mutants of G i proteins was observed in the FLAGhGPR20 expressing cells. These results suggest that hGPR20 continuously activates G i -type Gproteins.
Involvement of the DRY Motif of GPR20 in Activation of G i Proteins -Several reports have described the significance of a highly conserved stretch of amino acid residues located in the second intracellular loop of various GPCRs, Glu/Asp-Arg-Tyr, in G-protein activation (18, 19) . This domain is generally designated the DRY motif.
To obtain more evidence for the constitutive activation of G i proteins by GPR20, we examined whether the disruption of the DRY motif in hGPR20 (amino acids 147-149) affects G i activation. We constructed a mutant FLAGhGPR20, the R148A receptor, in which Asp 148 is substituted by Ala. The R148A receptor was expressed on the cell surface at levels similar to the wild-type FLAG-hGPR20, as judged by flow cytometric analysis (Fig. 5A ). As shown in Figure 5B , [
35 S]GTP S incorporation into membrane preparations from R148A receptor expressing cells was remarkably reduced compared to membranes from cells expressing the wild-type receptor. Additionally, the R148A receptor was not able to inhibit PGE 2 -induced cAMP formation (Fig. 5C ). All these results indicate that GPR20 is constitutively activated on the cell surface, leading to sustained activation of G i proteins, and that the DRY motif in hGPR20 plays a key role in activation of G i .
Increase in Basal cAMP Levels by Silencing of Endogenously Expressed GPR20 -Although we showed that overexpression of GPR20 resulted in constitutive activation of Gi proteins, those data were obtained by using overexpression systems. Therefore, we next examined whether or not a physiological expression level of GPR20 is enough to evoke the constitutive activation of Gi proteins. For this purpose, we performed an RNAi experiment using PC12h cells that endogenously express GPR20 (Fig. 2C) . We constructed three short hairpin RNA (shRNA) plasmids, pSilencer-sh1, pSilencer-sh2 and pSilencer-sh3, targeting the mRNA of rGPR20.
Transfection of each shRNA plasmid significantly reduced the endogenous rGPR20 mRNA in PC12h cells (Fig. 6A) . Introducing the most effective shRNA plasmid, pSilencer-sh3, into PC12h cells reduced the amount of rGPR20 mRNA by approximately 75% compared with control shRNA plasmid.
In PC12h cells possessing these rGPR20-shRNA plasmids, we observed moderate but reproducible increases in the basal cAMP level compared to levels in the presence of the control shRNA plasmid (Fig. 6B) . The results suggest that endogenous GPR20 also possesses constitutively or spontaneously active conformation.
Furthermore, we found that RNAi-mediated knockdown of GPR20 in PC12h cells resulted in an increase in [ 3 H]thymidine incorporation (Fig. 6C ). These findings suggest that intrinsic GPR20 is involved in the regulation of cell growth. Thus, the endogenous GPR20 attenuates the mitogenic signaling of PC12h cells possibly by control cellular cAMP level through G i activation.
DISCUSSION
We report here the expression pattern and characterization of an orphan GPCR, GPR20. We demonstrated that exogenously expressed hGPR20 elicits continuous activation of G i proteins in HEK293 cells in the absence of ligand. Cell responses, such as intracellular calcium mobilization and cAMP accumulation, were not elicited by stimulation with various kinds of lipids, nucleotides, or changes in extracellular pH. Although there is still the possibility that a specific agonist for hGPR20 exists in the culture medium, we observed no effect of increasing amounts of fatty acid-free BSA, which is known to trap and decrease free-lipids in the medium effectively, on the continuous activation of G i proteins by hGPR20 (data not shown). Furthermore, mutation of the Arg 148 residue in the hGPR20 DRY motif drastically abolished G i activation (Fig. 5) . Since the DRY motif is considered to maintain the receptor conformation (20, 21) , and especially the central Arg residue of this motif has been reported to be directly responsible for receptor-G-protein coupling (22), these results strongly support the hypothesis that GPR20 has the ability for continuous activation of G i proteins.
There are several lines of evidence that certain GPCRs are activated in the absence of specific agonists, and lead to a sustained transduction of various signals into cells (23).
Here, we present evidence that the exogenously expressed GPR20 activates G i proteins without any ligand stimulation in HEK293 cells. The ligand-independent activation of GPR20 was observed not only in HEK293 cells, but also in the rat hepatoma cell line RH7777 (data not shown). Although the constitutive activation of the exogenously expressed GPCR was sometimes observed due to an excess of the receptor in cultured cells (24), as shown in Fig. 4A , we demonstrated that at least GPR20 had a higher basal activity than hBLT1. Furthermore, GPR20 possibly forms a spontaneously active conformation in physiological conditions judging from the results of RNA knockdown using PC12h cells which intrinsically express GPR20 (Fig. 6) . In these cells, GPR20 may have a pivotal function in maintaining the intracellular cAMP levels via regulation of transcription and/or translation.
Moreover, we observed the mitogenic effect of the GPR20-silencing in PC12h cells. Several reports demonstrated that cAMP could stimulate cell proliferation by activating extracellular signal-regulated kinases (ERKs) in diverse cell types (25-27). According to previous reports, in B-Raf expressing cells, GTP-loaded Rap1 can activate B-Raf and the mitogen-activated protein (MAP) kinase cascade, and hormonal stimulation of cAMP/PKA/Rap1 in these cells activates ERKs (28). The expression of B-Raf was confirmed in PC12h cells (data not shown), and our findings that GPR20-silencing resulted in increases of cAMP production and cell proliferation are consistent with the above insight. These cAMP-mediated cell proliferation is induced by hormonal activation of GPCRs that are coupled to G s protein. It is still unclear whether ERKs are activated in the GPR20-silencing cells, our results provide a possibility that GPR20 expression in PC12h cells suppresses the cAMP-induced mitogenic signaling mediated by the other G s -coupled GPCRs.
The expression of GPR20 was ubiquitous in human and mouse tissues, with the highest levels of GPR20 mRNA detected in intestinal tissues. Previously, Allander et al. reported that GPR20 is abundantly expressed in gastrointestinal stromal tumors (GISTs), which are well known as the most common mesenchymal tumors of the digestive tracts (29). The expression of GPR20 was tightly correlated with expression of the proto-oncogene KIT, whose activation is a characteristic marker for GISTs in gene expression profiling.
Thus, GPR20 may be involved in the proliferation of intestinal cells.
qRT-PCR analysis also demonstrated that GPR20 is expressed in the brain and in various types of neuroblastoma cells (Fig. 2) . In a recently disclosed patent, a crucial role for GPR20 in the central nervous system has been proposed, because GPR20 deficient mice exhibit a hyperactivity disorder characterized by an increase in total distance traveled in an open field test (4). Since increased cAMP production might occur in some brain regions in GPR20 deficient mice, the abnormal cAMP levels in these areas may be related to the hyperactivity disorder (4) .
Intriguingly, it has been demonstrated that several orphan GPCRs, including GPR3 (30, 31), GPR6, GPR12 (32), GPR26, GPR78 (33), and GPR101 (34), have the ability to augment cAMP formation by constitutive activation of G s in a ligandindependent fashion.
Specifically, GPR26, GPR78, and GPR101 are expressed in some regions of the brain, including the caudate nuclei, putamen and the thalamus (33, 34), suggesting that they may counteract GPR20 in these areas. Because the intracellular cAMP level is essential for cellular homeostasis, including cell proliferation and differentiation, the amount of intracellular cAMP may be regulated by the balance in expression of these G i and G s -coupled receptors.
At present, a large number of GPCRs are defined as orphan receptors for which the cognate ligands have not yet been identified (1) . The first step in characterization of orphan GPCRs is identification of the natural agonists for these receptors, so-called deorphanization. Deorphanization of GPCRs has revolutionized many fields of biomedical research through discoveries of novel natural ligands. We have successfully identified a novel lysophosphatidic acid (LPA) receptor, LPA 4 (35), and the protonsensing behavior of G2A (13), TDAG8 (15) and 12-hydroxyheptadecatrienoic acid (12-HHT) as a novel agonist of leukotriene B 4 type2 receptor, BLT2 (36). The most common strategy for identifying ligands for orphan receptors is to seek effective agonists among appropriate ligand libraries or tissue extracts by monitoring various cellular responses using cells overexpressing the orphan receptor.
To be successful, it is necessary to know the appropriate assay format for a given orphan receptor, e.g., measurement of intracellular calcium mobilization or cAMP formation. However, it is still unclear which types of G-proteins are coupled to these orphan GPCRs. Thus, multiple assays are still required for this "blinded" ligand screening. In this report, we successfully demonstrate not only that GPR20 is functionally coupled to G i type Gproteins, but also that the coupled G i proteins are constitutively activated by GPR20 without any ligand stimulation, resulting in a modest suppression of basal cAMP levels. However, we cannot exclude the possibility that bona fide ligands for GPR20 exist in vivo. If GPR20 possesses a potential ability for acceleration of G i activation via the binding of specific agonists, the information obtained in this study will be helpful to develop efficient assay systems for screening specific ligands or inverse agonists.
In summary, our work demonstrates that GPR20 has the ability to activate G i proteins without extracellular triggers, indicating the pivotal role of this receptor in determining the basal tone of cAMP in cells. Furthermore, our findings suggest that the intrinsic expression of GPR20 is involved in the regulation of cell proliferation by controlling cellular cAMP level. In addition, if GPR20 has the potential to accelerate G-protein activation by ligand binding, screening efforts to identify bona fide or surrogate ligands for GPR20 will be required in order to delineate the exact functions of this receptor in vivo.
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Ballesteros, J., Jensen, A., Liapakis, G., Rasmussen, S., Shi, L., Gether, U., and Javitch, J. Figure 6 . Silencing of endogenous GPR20 by rGPR20-shRNA plasmids in PC12h cells. A, Three rGPR20-shRNA (pSilencer-sh1, -sh2 and -sh3) and control shRNA plasmids were transfected into PC12h cells. After culture in the presence of 300 μg/ml hygromycin for 7-9 days, the amounts of rGPR20 mRNA were measured as described in the Experimental Procedures. B, Effects of rGPR20 silencing on basal cAMP levels. The data are means ± S.E.M of a representative experiment from two independent experiments performed in quadruplicate. *, p < 0.05 (ANOVA with Tukey's multiple comparison test). C, Effects of rGPR20 silencing on cell proliferation. After culture in the presence of 300 μg/ml hygromycin for 7 days, 1 x 10 4 cells transfected with control shRNA plasmid (cont) or three rGPR20-shRNA plasmids (sh1, sh2 and sh3) were grown in a 96-well plate for 48 h with adding 1
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